Latest placebo Stories
"It’s simply magnificent.
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ -- - OPUS-2, a Phase 3 placebo-controlled study of lifitegrast 5.0%; results presented at
Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc.
Listen Live on Coast to Coast with George Noory as Dr.
-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc.
Palm tocotrienols may slow the progression of brain-degenerating white matter lesions MINNEAPOLIS, April 29, 2014 /PRNewswire/ -- While you may know about
TORONTO, April 28, 2014 /PRNewswire/ - Highland Therapeutics Inc.
New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced
Clinical Trials Point Toward 'ATX-101' as Potential Noninvasive Solution for Reduction of Submental Fat SAN FRANCISCO, April 26, 2014 /PRNewswire-USNewswire/ -- Skin laxity and fat buildup
- A poem in which the author retracts something said in an earlier poem.